Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 11 | 2011 | 367 | 1.170 |
Why?
|
| Medicaid | 4 | 2011 | 242 | 0.750 |
Why?
|
| Psychotropic Drugs | 2 | 2011 | 125 | 0.650 |
Why?
|
| Psychotic Disorders | 6 | 2010 | 140 | 0.590 |
Why?
|
| Anticonvulsants | 2 | 2006 | 372 | 0.420 |
Why?
|
| Polypharmacy | 1 | 2011 | 40 | 0.380 |
Why?
|
| Neoplasms | 3 | 2020 | 2751 | 0.360 |
Why?
|
| Platelet Aggregation | 2 | 2000 | 120 | 0.330 |
Why?
|
| Candidiasis | 2 | 2007 | 129 | 0.320 |
Why?
|
| Financing, Personal | 1 | 2008 | 10 | 0.320 |
Why?
|
| Medicare Part D | 1 | 2008 | 17 | 0.310 |
Why?
|
| Sodium-Hydrogen Exchangers | 2 | 1999 | 41 | 0.310 |
Why?
|
| Drug Therapy | 1 | 2008 | 87 | 0.300 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 1151 | 0.300 |
Why?
|
| Mental Disorders | 2 | 2011 | 824 | 0.280 |
Why?
|
| Antimanic Agents | 1 | 2007 | 37 | 0.280 |
Why?
|
| Fluconazole | 1 | 2007 | 47 | 0.280 |
Why?
|
| Hepatitis A Vaccines | 1 | 2006 | 10 | 0.280 |
Why?
|
| Aged | 24 | 2020 | 18998 | 0.280 |
Why?
|
| Hepatitis B Vaccines | 1 | 2006 | 42 | 0.270 |
Why?
|
| United States | 20 | 2020 | 10564 | 0.270 |
Why?
|
| Nitric Oxide | 2 | 2000 | 439 | 0.270 |
Why?
|
| Hospitalization | 6 | 2011 | 1731 | 0.260 |
Why?
|
| Incidence | 8 | 2020 | 3040 | 0.260 |
Why?
|
| Health Resources | 1 | 2007 | 116 | 0.260 |
Why?
|
| Schizophrenia | 2 | 2008 | 297 | 0.240 |
Why?
|
| SEER Program | 4 | 2019 | 194 | 0.240 |
Why?
|
| Intensive Care Units | 2 | 2007 | 483 | 0.230 |
Why?
|
| Antidepressive Agents | 1 | 2006 | 286 | 0.220 |
Why?
|
| Calcium | 2 | 1999 | 1097 | 0.220 |
Why?
|
| Drug Utilization | 4 | 2010 | 158 | 0.220 |
Why?
|
| Lung | 2 | 2021 | 1484 | 0.210 |
Why?
|
| Computer Simulation | 3 | 2014 | 616 | 0.210 |
Why?
|
| Middle Aged | 17 | 2020 | 25885 | 0.210 |
Why?
|
| Dementia | 5 | 2010 | 447 | 0.200 |
Why?
|
| Logistic Models | 7 | 2010 | 1788 | 0.200 |
Why?
|
| Adult | 14 | 2020 | 28944 | 0.190 |
Why?
|
| Vaccination | 1 | 2006 | 949 | 0.190 |
Why?
|
| Thrombin | 2 | 1999 | 60 | 0.190 |
Why?
|
| Aged, 80 and over | 11 | 2014 | 6343 | 0.190 |
Why?
|
| Azores | 1 | 2020 | 2 | 0.180 |
Why?
|
| Portugal | 1 | 2020 | 7 | 0.180 |
Why?
|
| Models, Statistical | 3 | 2019 | 450 | 0.180 |
Why?
|
| Models, Genetic | 2 | 2014 | 748 | 0.180 |
Why?
|
| Male | 26 | 2021 | 59957 | 0.180 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 151 | 0.180 |
Why?
|
| Female | 27 | 2021 | 65361 | 0.180 |
Why?
|
| Nursing Homes | 3 | 2010 | 95 | 0.170 |
Why?
|
| Endothelium, Vascular | 2 | 2000 | 514 | 0.170 |
Why?
|
| Adolescent | 10 | 2021 | 19043 | 0.170 |
Why?
|
| Lipoproteins, HDL | 1 | 2000 | 96 | 0.170 |
Why?
|
| Prostatic Neoplasms | 3 | 2019 | 1518 | 0.170 |
Why?
|
| Bronchial Neoplasms | 1 | 2019 | 16 | 0.170 |
Why?
|
| History, 21st Century | 1 | 2020 | 271 | 0.160 |
Why?
|
| Software | 2 | 2014 | 673 | 0.160 |
Why?
|
| Prevalence | 4 | 2011 | 2390 | 0.160 |
Why?
|
| Retrospective Studies | 14 | 2011 | 15934 | 0.160 |
Why?
|
| Young Adult | 6 | 2020 | 8830 | 0.150 |
Why?
|
| Humans | 32 | 2021 | 122971 | 0.150 |
Why?
|
| Child, Preschool | 7 | 2021 | 13858 | 0.150 |
Why?
|
| Colon | 1 | 2020 | 355 | 0.150 |
Why?
|
| Organoids | 1 | 2020 | 275 | 0.150 |
Why?
|
| Infant | 6 | 2021 | 12355 | 0.150 |
Why?
|
| Drug Prescriptions | 2 | 2011 | 215 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2019 | 384 | 0.140 |
Why?
|
| Forecasting | 1 | 2018 | 355 | 0.130 |
Why?
|
| Georgia | 2 | 2006 | 29 | 0.130 |
Why?
|
| Infant, Newborn | 5 | 2021 | 8120 | 0.130 |
Why?
|
| Age Factors | 5 | 2011 | 2799 | 0.130 |
Why?
|
| Stem Cells | 1 | 2021 | 713 | 0.130 |
Why?
|
| Thyroid Neoplasms | 2 | 2017 | 193 | 0.130 |
Why?
|
| Antiviral Agents | 1 | 2020 | 736 | 0.130 |
Why?
|
| United States Food and Drug Administration | 3 | 2020 | 147 | 0.120 |
Why?
|
| Child | 8 | 2021 | 24170 | 0.120 |
Why?
|
| Blood Platelets | 1 | 1998 | 333 | 0.120 |
Why?
|
| Risk | 4 | 2011 | 747 | 0.120 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 4 | 0.120 |
Why?
|
| Rabbits | 3 | 2000 | 717 | 0.110 |
Why?
|
| Cross-Sectional Studies | 6 | 2011 | 3342 | 0.110 |
Why?
|
| Health Care Surveys | 3 | 2009 | 284 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 562 | 0.110 |
Why?
|
| Residence Characteristics | 3 | 2008 | 265 | 0.100 |
Why?
|
| Prescriptions | 2 | 2009 | 39 | 0.100 |
Why?
|
| Socioeconomic Factors | 3 | 2010 | 866 | 0.100 |
Why?
|
| Losartan | 1 | 2011 | 33 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 56 | 0.090 |
Why?
|
| Valine | 1 | 2011 | 106 | 0.090 |
Why?
|
| Tetrazoles | 1 | 2011 | 63 | 0.090 |
Why?
|
| Time Factors | 3 | 2011 | 6216 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 203 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2010 | 402 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 1412 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2011 | 128 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 121 | 0.090 |
Why?
|
| Off-Label Use | 1 | 2010 | 25 | 0.090 |
Why?
|
| Homes for the Aged | 1 | 2010 | 24 | 0.090 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 32 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2011 | 4688 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 210 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 117 | 0.080 |
Why?
|
| Hematinics | 1 | 2010 | 57 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2010 | 106 | 0.080 |
Why?
|
| Drug Utilization Review | 1 | 2009 | 33 | 0.080 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 25 | 0.080 |
Why?
|
| Sexual Behavior | 1 | 2010 | 234 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2010 | 181 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2010 | 498 | 0.080 |
Why?
|
| Cattle | 2 | 2000 | 559 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2010 | 1308 | 0.080 |
Why?
|
| Heart Failure | 2 | 2011 | 2125 | 0.080 |
Why?
|
| Military Personnel | 1 | 2010 | 206 | 0.080 |
Why?
|
| Risk Factors | 6 | 2021 | 9950 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2020 | 969 | 0.070 |
Why?
|
| Lithium Compounds | 1 | 2007 | 14 | 0.070 |
Why?
|
| Drug Resistance, Fungal | 1 | 2007 | 25 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2007 | 49 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2007 | 71 | 0.070 |
Why?
|
| Hepatitis A | 1 | 2006 | 32 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2007 | 102 | 0.070 |
Why?
|
| Lymphoma | 1 | 2010 | 324 | 0.070 |
Why?
|
| Emergency Service, Hospital | 3 | 2010 | 1067 | 0.070 |
Why?
|
| Valproic Acid | 1 | 2007 | 165 | 0.070 |
Why?
|
| Affect | 1 | 2007 | 154 | 0.070 |
Why?
|
| Drug Labeling | 1 | 2006 | 26 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 611 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 366 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 252 | 0.060 |
Why?
|
| Anemia | 1 | 2010 | 340 | 0.060 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2006 | 94 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2011 | 12083 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2006 | 162 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 117 | 0.060 |
Why?
|
| Depression | 2 | 2010 | 1220 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 821 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2007 | 293 | 0.060 |
Why?
|
| Survivors | 1 | 2007 | 346 | 0.060 |
Why?
|
| Urban Population | 1 | 2005 | 218 | 0.060 |
Why?
|
| Vancomycin | 1 | 2006 | 217 | 0.060 |
Why?
|
| Algorithms | 2 | 2010 | 1583 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 259 | 0.060 |
Why?
|
| Cross Infection | 1 | 2006 | 332 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1689 | 0.050 |
Why?
|
| Bacteremia | 1 | 2006 | 405 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 791 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2025 | 0.050 |
Why?
|
| Length of Stay | 1 | 2007 | 1281 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 1834 | 0.050 |
Why?
|
| Viral Tropism | 1 | 2020 | 34 | 0.040 |
Why?
|
| Drug Approval | 1 | 2020 | 39 | 0.040 |
Why?
|
| Virus Internalization | 1 | 2020 | 54 | 0.040 |
Why?
|
| Immune System | 1 | 2021 | 86 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2021 | 83 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 183 | 0.040 |
Why?
|
| Cohort Effect | 1 | 2019 | 5 | 0.040 |
Why?
|
| Propensity Score | 2 | 2011 | 203 | 0.040 |
Why?
|
| Nitroarginine | 1 | 1999 | 11 | 0.040 |
Why?
|
| HIV Infections | 1 | 2010 | 1862 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 186 | 0.040 |
Why?
|
| Nigericin | 1 | 1998 | 2 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 1998 | 25 | 0.040 |
Why?
|
| Animals | 4 | 2020 | 33923 | 0.040 |
Why?
|
| Biological Transport, Active | 1 | 1998 | 87 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 1999 | 221 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 267 | 0.040 |
Why?
|
| Anxiety | 3 | 2009 | 953 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1101 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 1301 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 1256 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1999 | 256 | 0.030 |
Why?
|
| Kidney Pelvis | 1 | 2017 | 43 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 99 | 0.030 |
Why?
|
| Aorta | 1 | 2000 | 540 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 76 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 112 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2011 | 1164 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 118 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 2396 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 28 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 1999 | 517 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 254 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2000 | 3075 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 234 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 404 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 388 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 265 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 431 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 664 | 0.030 |
Why?
|
| Models, Structural | 1 | 2011 | 49 | 0.020 |
Why?
|
| Valsartan | 1 | 2011 | 21 | 0.020 |
Why?
|
| Fosinopril | 1 | 2011 | 5 | 0.020 |
Why?
|
| Lisinopril | 1 | 2011 | 25 | 0.020 |
Why?
|
| Enalapril | 1 | 2011 | 18 | 0.020 |
Why?
|
| Captopril | 1 | 2011 | 28 | 0.020 |
Why?
|
| Nigeria | 1 | 2010 | 79 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 688 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 48 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 8 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2010 | 3648 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2010 | 85 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 93 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 376 | 0.020 |
Why?
|
| Texas | 2 | 2010 | 3542 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 193 | 0.020 |
Why?
|
| Social Class | 1 | 2010 | 181 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 670 | 0.020 |
Why?
|
| Veterans | 2 | 2011 | 1721 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 367 | 0.020 |
Why?
|
| Social Behavior | 1 | 2010 | 206 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 383 | 0.020 |
Why?
|
| Quetiapine Fumarate | 1 | 2008 | 14 | 0.020 |
Why?
|
| Dibenzothiazepines | 1 | 2008 | 12 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 24 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2824 | 0.020 |
Why?
|
| Health Policy | 1 | 2010 | 208 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2008 | 99 | 0.020 |
Why?
|
| Risperidone | 1 | 2008 | 56 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1586 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1170 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2006 | 24 | 0.020 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2006 | 117 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 1389 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1473 | 0.020 |
Why?
|
| Genome, Human | 1 | 2013 | 1261 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1246 | 0.020 |
Why?
|
| ROC Curve | 1 | 2006 | 554 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 731 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2011 | 697 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 17647 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 2029 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2010 | 3257 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2006 | 1240 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2006 | 385 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 2846 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 5025 | 0.010 |
Why?
|
| Quality of Life | 1 | 2010 | 1921 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1682 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 6020 | 0.010 |
Why?
|